ACADIA Pharmaceuticals Inc (ACAD) support and resistance · P/E 15, rev $576.0M
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
This page maps ACADIA Pharmaceuticals Inc (ACAD) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ACAD 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ACAD quote page for the session range and the stock page for the full model.
Not investment advice.